

| Catalog No. | CY257016 | ||||
|---|---|---|---|---|---|
| Description |
Blontuvetmab (CY257016) is a research-grade recombinant antibody targeting CD20. Produced in mammalian cells with native-like glycosylation.
Highlights
|
||||
| Species reactivity | Canine | ||||
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo | ||||
| Host species | Canine | ||||
| Isotype | IgG2-kappa-lambda | ||||
| Expression system | Mammalian cells | ||||
| Clonality | Monoclonal | ||||
| Target | CD20/MS4A1 | ||||
| Endotoxin level | Please contact the lab for this information. | ||||
| Purity | >95% purity as determined by SDS-PAGE. | ||||
| Purification | Protein A/G purified from cell culture supernatant. | ||||
| Accession | Q3C2E2 | ||||
| Form | Liquid | ||||
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
||||
| Product Usage Information |
| ||||
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||
| Alternate Names | AT-004, VT-007, 1608112-78-2 | ||||
| Background | B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). | ||||
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Blontuvetmab.


Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-87433958
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский